Culture

Higher red cell transfusion threshold offers no advantage for treating preterm infants

Very low birthweight infants often need blood transfusions to survive. A National Institutes of Health-funded study suggests that providing a higher threshold of red cells within accepted limits offers no advantage in survival or reduction in neurological impairment over a lower threshold. The research was conducted by Haresh Kirpalani, B.M., of the University of Pennsylvania, Philadelphia, and colleagues and was funded by the NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute, and National Center for Advancing Translational Sciences. The study appears in The New England Journal of Medicine.

Very preterm infants (born before 29 weeks of pregnancy) and those weighing less than 1,000 grams (slightly more than 2 pounds) are at high risk for anemia because of their early stage of development, reduced ability to produce red blood cells and need for increased blood sampling as part of their intensive medical care. Previous studies suggest that anemic infants would have a lower risk of death, cognitive delay, cerebral palsy and hearing and vision loss if they received transfusions leading to higher hemoglobin thresholds within the currently accepted range. Measuring hemoglobin, a protein produced in red blood cells, indicates the proportion of red blood cells. Hemoglobin transfusion thresholds for preterm infants vary according to weight, stage of maturity and other factors.

Of 845 infants assigned to a higher hemoglobin threshold, 50.1% died or survived with a neurodevelopmental impairment, compared to 49.8% of 847 infants assigned to a lower threshold. When the two component outcomes were evaluated separately, the two groups also had similar rates of death (16.2% vs. 15%) and of neurodevelopmental impairment (39.6% vs 40.3%). The authors conclude that a higher hemoglobin threshold increased the number of transfusions, but did not improve the chance of survival without neurodevelopmental impairment.

Credit: 
NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development

Frailty is a factor in higher mortality for women awaiting liver transplants

Women awaiting liver transplants in the United States are known to be about one-third more likely than men to become too ill to undergo surgery or die before receiving a liver. Now a study headed by UC San Francisco and Columbia University highlights the role that frailty plays in this gender gap.

The study followed 1,405 patients with cirrhosis, of whom 41 percent were women, awaiting liver transplantation at nine transplant centers in the United States. The men, whose ages ranged from 49 to 63, were more likely to have chronic hepatitis C and alcoholic liver disease (27 percent versus 22, and 33 percent versus 19 percent). The women, whose ages ranged from 50 to 63, were more likely to have non-alcoholic fatty liver disease and autoimmune cholestatic liver disease (23 percent versus 16 percent, and 23 percent versus 9 percent).

The researchers, led by first author Jennifer Lai, MD, MBA, a general and transplant hepatologist at the UCSF Department of Medicine, found that both genders had similar levels of liver disease severity, but fewer women had high blood pressure and coronary artery disease. Despite this, they were significantly frailer according to testing using the Liver Frailty Index (LFI), which showed weaker gender-adjusted grip, worse balance and that they were slower to stand up from a sitting position.

"This is the first time that frailty has been identified and quantified as a risk factor among women with cirrhosis who are waiting for liver transplants," said Lai. "The importance of this finding is that this gender gap can potentially be mitigated through early interventions as basic as providing adequate caloric and protein intake and engaging in regular exercise. Clinicians can advise women on diet and exercise interventions that build strength." These steps may be helpful for women undergoing other organ transplants, since frailty may play a role there too, the authors noted.

While the causes of frailty were not explored, Lai said that it is generally attributed to physical inactivity, chronic liver failure and poor diet.

Over the course of the study, the women had a 36 percent higher risk of waitlist mortality, which was defined as death or delisting for being too sick for transplantation. After adjusting for LFI scores and other variables, the researchers concluded that frailty accounted for 13 percent of the gender gap in waitlist mortality. While the study does not address the other factors that make up for the gender disparity, the authors note differences in kidney function and the higher percentage of male donors, who may be poor matches for women given their smaller stature.

The greatest significance of the study, said Lai, is at the level of the population of liver transplant patients in the United States.

"The waitlist mortality gender gap has persisted for 15 years across the entire U.S. liver transplant system and will continue to persist if it is not recognized," she said. Fortunately, "now that it has been recognized, it can be addressed."

Credit: 
University of California - San Francisco

Novel public-private partnership facilitates development of fusion energy

image: PPPL physicist Gerrit Kramer with conceptual image of SPARC fusion reactor.

Image: 
Collage and Kramer photo by Elle Starkman/PPPL Office of Communications. SPARC image courtesy of Commonwealth Fusion Systems.

The U.S. Department of Energy's (DOE) Princeton Plasma Physics Laboratory (PPPL) is collaborating with private industry on cutting-edge fusion research aimed at achieving commercial fusion energy. This work, enabled through a public-private DOE grant program, supports efforts to develop high-performance fusion grade plasmas. In one such project PPPL is working in coordination with MIT's Plasma Science and Fusion Center (PSFC) and Commonwealth Fusion Systems, a start-up spun out of MIT that is developing a tokamak fusion device called "SPARC."

The goal of the project is to predict the leakage of fast "alpha" particles produced during the fusion reactions in SPARC, given the size and potential misalignments of the superconducting magnets that confine the plasma. These particles can create a largely self-heated or "burning plasma" that fuels fusion reactions. Development of burning plasma is a major scientific goal for fusion energy research. However, leakage of alpha particles could slow or halt the production of fusion energy and damage the interior of the SPARC facility.

New superconducting magnets

Key features of the SPARC machine include its compact size and powerful magnetic fields enabled by the ability of new superconducting magnets to operate at higher fields and stresses than existing superconducting magnets. These features will enable design and construction of smaller and less-expensive fusion facilities, as described in recent publications by the SPARC team -- assuming that the fast alpha particles created in fusion reactions can be contained long enough to keep the plasma hot.

"Our research indicates that they can be," said PPPL physicist Gerrit Kramer, who participates in the project through the DOE Innovation Network for Fusion Energy (INFUSE) program. The two-year-old program, which PPPL physicist Ahmed Diallo serves as deputy director, aims to speed private-sector development of fusion energy through partnerships with national laboratories.

Well-confined

"We found that the alpha particles are indeed well confined in the SPARC design," said Kramer, coauthor of a paper in the Journal of Plasma Physics that reports the findings. He worked closely with the lead author Steven Scott, a consultant to Commonwealth Fusion Systems and former long-time physicist at PPPL.

Kramer used the SPIRAL computer code developed at PPPL to verify the particle confinement. "The code, which simulates the wavy pattern, or ripples, in a magnetic field that could allow the escape of fast particles, showed good confinement and lack of damage to the SPARC walls," Kramer said. Moreover, he added, "the SPIRAL code agreed well with the ASCOT code from Finland. While the two codes are completely different, the results were similar."

The findings gladdened Scott. "It's gratifying to see the computational validation of our understanding of ripple-induced losses," he said, "since I studied the issue experimentally back in the early 1980s for my doctoral dissertation."

Fusion reactions combine light elements in the form of plasma -- the hot, charged state of matter composed of free electrons and atomic nuclei, or ions, that comprises 99 percent of the visible universe -- to generate massive amounts of energy. Scientists around the world are seeking to create fusion as a virtually unlimited source of power for generating electricity.

Key guidance

Kramer and colleagues noted that misalignment of the SPARC magnets will increase the ripple-induced losses of fusion particles leading to increased power striking the walls. Their calculations should provide key guidance to the SPARC engineering team about how well the magnets must be aligned to avoid excessive power loss and wall damage. Properly aligned magnets will enable studies of plasma self-heating for the first time and development of improved techniques for plasma control in future fusion power plants.

Credit: 
DOE/Princeton Plasma Physics Laboratory

Largest study of Asia's rivers unearths 800 years of paleoclimate patterns

image: Map of the Asian Monsoon region; river basins involved in this study are highlighted by subregion, rivers belonging to the world's 30 biggest are shown with names indicated in blue.

Image: 
SUTD

813 years of annual river discharge at 62 stations, 41 rivers in 16 countries, from 1200 to 2012. That is what researchers at the Singapore University of Technology and Design (SUTD) produced after two years of research in order to better understand past climate patterns of the Asian Monsoon region.

Home to many populous river basins, including ten of the world's biggest rivers (Figure 1), the Asian Monsoon region provides water, energy, and food for more than three billion people. This makes it crucial for us to understand past climate patterns so that we can better predict long term changes in the water cycle and the impact they will have on the water supply.

To reconstruct histories of river discharge, the researchers relied on tree rings. An earlier study by Cook et al. (2010) developed an extensive network of tree ring data sites in Asia and created a paleodrought record called the Monsoon Asia Drought Atlas (MADA). SUTD researchers used the MADA as an input for their river discharge model.

They developed an innovative procedure to select the most relevant subset of the MADA for each river based on hydroclimatic similarity. This procedure allowed the model to extract the most important climate signals that influence river discharge from the underlying tree ring data.

"Our results reveal that rivers in Asia behave in a coherent pattern. Large droughts and major pluvial periods have often occurred simultaneously in adjacent or nearby basins. Sometimes, droughts stretched as far as from the Godavari in India to the Mekong in Southeast Asia (Figure 2). This has important implications for water management, especially when a country's economy depends on multiple river basins, like in the case of Thailand," explained first author Nguyen Tan Thai Hung, a PhD student from SUTD.

Using modern measurements, it has been known that the behaviour of Asian rivers is influenced by the oceans. For instance, if the Pacific Ocean becomes warmer in its tropical region in an El Nino event, this will alter atmospheric circulations and likely cause droughts in South and Southeast Asian rivers. However, the SUTD study revealed that this ocean-river connection is not constant over time. The researchers found that rivers in Asia were much less influenced by the oceans in the first half of the 20th century compared to the 50 years before and 50 years after that period.

"This research is of great importance to policy makers; we need to know where and why river discharge changed during the past millennium to make big decisions on water-dependent infrastructure. One such example is the development of the ASEAN Power Grid, conceived to interconnect a system of hydropower, thermoelectric, and renewable energy plants across all ASEAN countries. Our records show that 'mega-droughts' have hit multiple power production sites simultaneously, so we can now use this information to design a grid that is less vulnerable during extreme events," said principal investigator Associate Professor Stefano Galelli from SUTD.

Credit: 
Singapore University of Technology and Design

LSU Health New Orleans discovers potential new RX strategy for stroke

New Orleans, LA - Research conducted at LSU Health New Orleans Neuroscience Center of Excellence reports that a combination of an LSU Health-patented drug and selected DHA derivatives is more effective in protecting brain cells and increasing recovery after stroke than a single drug. The findings are published in Brain Circulation, available here.

Nicolas Bazan, MD, PhD, Boyd Professor, Professor of Neurology and Director of the Neuroscience Center of Excellence at LSU Health New Orleans School of Medicine, and Ludmila Belayev, MD, LSU Health New Orleans Professor of Neuroscience, Neurology, and Neurosurgery, discovered this novel therapeutic strategy for ischemic stroke using an experimental model.

During an ischemic stroke, signals are produced from arriving blood white cells and primary brain immune cells called microglia that cause neuroinflammation leading to a buildup of chemicals that harm the brain. Platelet-activating factor (PAF) accumulates, and inhibition of this process plays a critical role in neuronal survival. Dr. Bazan's earlier studies also showed that in addition to its anti-inflammatory properties, DHA, an essential omega-3 fatty acid, stimulates the production of Neuroprotectin D1 (NPD1), a molecule that protects brain cells and promotes their survival. One complicating factor in developing neuroprotective strategies for stroke are the multiple routes and events that occur in the brain during a stroke, which has been approached mainly by monotherapeutic agents that were mostly unsuccessful.

Because no single therapy has proven effective in treating the complexity of stroke, the team aimed at two different events - blocking pro-inflammatory platelet-activating factor receptors (PAF-R) and activating cell-survival pathways. They found that treatment with LAU-0901, a synthetic molecule discovered in the Bazan lab that blocks pro-inflammatory platelet-activating factor, plus aspirin-triggered NPD1 (AT-NPD1) reduced the size of the damaged area in the brain, initiated repair mechanisms, and remarkably improved behavioral recovery.

Total lesion volumes were reduced with LAU?0901 plus NPD1 by 62% and LAU?0901 plus AT?NPD1 by 90%. Combinatory treatment with LAU?0901 plus AT?NPD1 improved the behavioral score up to 54% on day three. LAU?0901 and LAU?0901 plus DHA decreased the production of 12?hydroxyeicosatetraenoic acid, a pro?inflammatory mediator.

"The biological activity of LAU-0901 and AT-NPD1 is due to specific activation or modulation of signaling pathways associated with the immune system, inflammation, cell survival, and cell-cell interactions," notes Dr. Bazan. "These findings provide a major conceptual advance of broad therapeutic relevance for cell survival, brain function and, particularly, stroke and neurodegenerative diseases."

"We discovered that these novel molecules promote neuronal cell survival with important anti-inflammatory activity," explains Dr. Belayev. "This combinatorial therapy may hold promise for future therapeutic development against ischemic stroke."

According to the Centers for Disease Control and Prevention, someone in the United States has a stroke every 40 seconds. Every 4 minutes, someone dies of stroke. Every year, more than 795,000 people in the United States have a stroke. About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked. Stroke-related costs in the United States came to nearly $46 billion between 2014 and 2015. This total includes the cost of health care services, medicines to treat stroke, and missed days of work. Stroke is a leading cause of serious long-term disability. Stroke reduces mobility in more than half of stroke survivors age 65 and over.

Credit: 
Louisiana State University Health Sciences Center

New research may explain severe virus attacks on the lungs

image: The development of human macrophages.

Image: 
The research team.

In some cases, immune cells in the lungs can contribute to worsening a virus attack. In a new study, researchers at Karolinska Institutet in Sweden describe how different kinds of immune cells, called macrophages, develop in the lungs and which of them may be behind severe lung diseases. The study, which was published in Immunity, may contribute to future treatments for COVID-19, among other diseases.

The structure of the lungs exposes them to viruses and bacteria from both the air and the blood. Macrophages are immune cells that, among other things, protect the lungs from such attacks. But under certain conditions, lung macrophages can also contribute to severe lung diseases, such as chronic obstructive pulmonary disease (COPD) and COVID-19.

To date, research on the development of human lung macrophages has been limited.

Macrophages can have different origins and develop, among other things, from white blood cells, monocytes, that are divided into different genetically determined main types. In humans, two of these are "classical" CD14+ monocytes and "non-classical" CD16+ monocytes.

In a new study at Karolinska Institutet, researchers have used a model to study the development of lung macrophages directly in a living lung. This has been combined with a method to study gene activity in individual cells, RNA sequencing, and thereby discovered how blood monocytes become human lung macrophages.

"In our study, we show that classical monocytes migrate into airways and lung tissue and are converted into macrophages that protect the health and function of the lungs. We have also identified a special kind of monocyte, HLA-DRhi, which is an intermediate immune cell between a blood monocyte and an airway macrophage. These HLA-DRhi monocytes can leave the blood circulation and migrate into the lung tissue," says Tim Willinger, Associate Professor at the Department of Medicine, Huddinge, Karolinska Institutet, who led the study.

The non-classical monocytes, however, develop into macrophages in the many blood vessels of the lungs and do not migrate into the lung tissue.

"Certain macrophages in the lungs probably have a connection to a number of severe lung diseases. In respiratory infections, for example, monocytes in the lungs develop into macrophages, which combat viruses and bacteria. But a certain type of macrophage may also contribute to severe inflammation and infections," says the study's first author Elza Evren, a doctoral student in Tim Willinger's research team.

In an infection with the novel coronavirus, SARS-COV-2, which causes COVID-19, researchers believe that protective, anti-inflammatory macrophages are replaced by pro-inflammatory lung macrophages from blood monocytes.

"The existence of these blood monocyte-derived macrophages has been shown in other studies to correlate with how severely ill a person becomes in COVID-19 and how extensive the damage to the lungs is. Patients with severe COVID-19 also have fewer HLA-DRhi monocytes in their blood, probably because they move away from the blood into the lungs. Given their important role in rapid inflammatory responses, our results indicate that future treatments should focus on inflammatory macrophages and monocytes to reduce lung damage and mortality from severe COVID-19," says Tim Willinger.

Credit: 
Karolinska Institutet

Scientists explore deficits in processing speed in individuals with spinal cord injury

image: Dr. Wylie is director of the Rocco Ortenzio Neuroimaging Center at Kessler Foundation.

Image: 
Kessler Foundation/Jody Banks

East Hanover, NJ. December 30, 2020. A team of rehabilitation researchers has studied processing speed deficits in individuals with spinal cord injury (SCI), comparing their brain activation patterns with those of healthy age-matched controls, and older healthy individuals. They found that the SCI group and older controls had similar activation patterns, but the SCI group differed significantly from their age-matched controls.

The article, "The neural mechanisms underlying processing speed deficits in individuals who have sustained a spinal cord injury: A pilot study" (doi: 10.1007/s10548-020-00798-x) was epublished on September 25, 2020 by Brain Topography. The authors are scientists with expertise in research in cognitive rehabilitation and SCI rehabilitation: Glenn Wylie, DPhil, Nancy D. Chiaravalloti, PhD, Erica Weber, PhD, Helen Genova, PhD, and Trevor Dyson-Hudson, MD, from Kessler Foundation, and Jill M. Wecht, EdD, from the James J. Peters VA Medical Center.

Individuals with chronic SCI have an increased risk for cognitive deficits that resemble the deficits associated with the aging process, giving rise to the theory of "accelerated cognitive aging." As reported previously by this team, the deficits affect processing speed, new learning and memory, and verbal fluency, which are the domains affected during aging. This study is the first to examine the neural mechanisms of higher order cognitive tasks of individuals with SCI. The focus was on processing speed, which is known to be affected by SCI and aging, and is integral to cognitive function and everyday life activities.

The 30 participants were participants of a larger study who underwent optional neuroimaging studies at the Rocco Ortenzio Neuroimaging Center at Kessler Foundation -- 10 individuals with cervical SCI, 10 age-matched controls, and 10 healthy older individuals. In addition to traditional neuropsychological testing methods, processing speed was tested in the scanner, using timed letter comparison tasks during functional magnetic resonance imaging (fMRI). This study was the first to use the modified letter comparison test.

Significant differences in brain activation were found between the SCI group and the age-matched control group, but the SCI and older groups had similar patterns, including activation of the hippocampal, frontal and parietal areas. "This suggests that individuals with SCI are compensating for deficits in processing speed by relying on the areas of the brain involved in executive control and memory," noted Dr. Chiaravalloti, "which supports the theory of accelerated brain aging after SCI."

Despite the limitations of sample size and level of injury, the study is an important contribution to our understanding of the impact of SCI on cognition, according to Dr. Wylie, director of the Ortenzio Center. "Our ability to observe brain activation while the individual performs specific cognitive tasks provides new information on the mechanisms that underlie the cognitive deficits that we now know affect a substantial proportion of the SCI population," Dr. Wylie said. "Developing treatments targeted to these deficits depends on our pursuit of this line of research, which may benefit other populations affected by delayed processing speed."

Credit: 
Kessler Foundation

Published data from Moderna COVID-19 vaccine trial show 94.1 percent efficacy

BOSTON -- A peer-reviewed paper published in The New England Journal of Medicine provides data from the much-anticipated COVE study, which evaluated mRNA-1273, a vaccine candidate against COVID-19 manufactured by Moderna, Inc. Results from the primary analysis of the study, which will continue for two years, provide evidence that the vaccine can prevent symptomatic infection. Among the more than 30,000 participants randomized to receive the vaccine or a placebo, 11 of those in the vaccine group developed symptomatic COVID-19 compared to 185 participants who received the placebo, demonstrating 94.1 percent efficacy in preventing symptomatic COVID-19. Cases of severe COVID-19 occurred only in participants who received the placebo.

Brigham and Women's Hospital served as a site for the trial as part of the COVID-19 Prevention Network (CoVPN), funded by the National Institutes of Health. In addition, Lindsey Baden, MD, an infectious diseases specialist at the Brigham and an expert in vaccine development for viral diseases, served as co-principal investigator for the study and lead author of the paper.

"Our work continues. Over the next months, we'll have increasing amounts of data to better define how this vaccine works, but the results so far show a 94.1 percent efficacy. These numbers are compelling," said Baden. "And, importantly, the data suggest protection from severe illness, indicating that the vaccine could have an impact on preventing hospitalizations and deaths, at least in the first several months post-vaccination."

The study enrolled 30,420 adult participants at 99 U.S. sites, including over 600 participants enrolled at the Brigham. Eligible participants were 18 years old or older with no known history of SARS-CoV-2 infection, and whose locations or circumstances put them at appreciable risk of SARS-CoV-2 infection and/or high risk of severe COVID-19. The race and ethnicity proportions of the trial were generally representative of U.S. demographics (79 percent white; 10 percent Black or African American; 20 percent Hispanic or Latino participants).

Participants received their first injection between July 27 and Oct. 23, 2020, followed by a second injection 28 days later. Each injection, given intramuscularly, had a volume of 0.5 mL, containing 100 μg of mRNA-1273 or saline placebo.

In the placebo group, 185 participants developed symptomatic COVID-19 illness; in the vaccine group, 11 participants did. In secondary analyses, the vaccine's efficacy was similar across groups of key interest, including those who already had antibodies against SARS-CoV-2 at the time of enrollment (indicating previous infection with COVID-19) and among those who were 65 years of age or older. Thirty participants had severe COVID-19 -- all in the placebo group.

Starting from randomization, cases of COVID-19 and severe COVID-19 were continuously monitored throughout the trial by the Data Safety Monitoring Board, empaneled by the NIAID. Participants were closely monitored for adverse events in the weeks following their injection. Investigators have collected and will continue to collect data on any serious adverse events or adverse events that require medical attention through two years post-injection.

Overall, reactions to the vaccine were mild -- about half of recipients experienced fatigue, muscle aches, joint pain and headaches, more so after the second dose. In most cases, these effects started about 15 hours after the vaccine and resolved after two days without sequelae. A similar number of adverse events were reported in the placebo and vaccine groups.

"While these results are encouraging, they are limited by the short duration of follow-up so far. Longer term data from the ongoing study may allow us to more carefully evaluate the vaccine's efficacy among different groups, determine the impact on asymptomatic infection, understand when immunity wanes, and determine whether vaccines affect infectiousness," said Baden. "But we shouldn't lose sight of the progress that we have made, which shows what is possible when we come together to tackle an immensely challenging problem."

Credit: 
Brigham and Women's Hospital

Sustained cellular immune dysregulation in individuals recovering from COVID-19

image: Nathaniel Erdmann

Image: 
UAB

BIRMINGHAM, Ala. - COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path.

Many infected patients remain asymptomatic or have mild symptoms. Others, especially those with comorbidities, can develop severe clinical disease with atypical pneumonia and multiple system organ failure.

Since the first cases were reported in December 2019, the SARS-CoV-2 virus that causes COVID-19 has surged into a pandemic, with cases and deaths still mounting. Ongoing observational clinical research has become a priority to better understand how this previously unknown virus acts, and findings from this research can better inform treatment and vaccine design.

University of Alabama at Birmingham researchers, led by first-author Jacob "Jake" Files and co-senior authors Nathan Erdmann, M.D., Ph.D., and Paul Goepfert, M.D., have now reported their observational study, "Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection," published in the Journal of Clinical Investigation.

In a commentary on the UAB study, published in the same issue, Phillip Mudd, M.D., Ph.D., and Kenneth Remy, M.D., both of Washington University, wrote, "The importance of these studies to provide context for the interpretation of immune responses generated by participants in COVID-19 vaccine trials, including how those responses change over time, cannot be over-emphasized. This information will be key in potential modifications to existing COVID-19 vaccines and treatments."

The UAB researchers obtained blood samples and clinical data from 46 hospitalized COVID-19 patients and 39 non-hospitalized individuals who had recovered from confirmed COVID-19 infection. Both groups were compared to healthy, COVID-19-negative controls. Importantly, most individuals in the hospitalized group had active SAR-CoV-2 viruses in their blood and were in the hospital at the time of sample collection. All individuals in the non-hospitalized group were convalescent at the time of sample collection.

From the blood samples, researchers were able to separate specific immune cell subsets and analyze cell surface markers. From this complex information, immunologists can analyze how each individual's immune system is responding during infection and during convalescence. Some of these results can reveal whether immune cells have become activated and exhausted by the infection. Exhausted immune cells may increase susceptibility to a secondary infection or hamper development of protective immunity to COVID-19.

In addition, the researchers were able to analyze changes over time, in two ways. The first was observing changes in surface markers over time, defined as days since the onset of symptoms for non-hospitalized samples. The second was directly comparing the frequencies of these markers between the first and second clinic visits for non-hospitalized patients who had blood samples collected at two sequential timepoints.

The most surprising finding involved non-hospitalized patients. While the UAB researchers saw upregulated activation markers in hospitalized patients, they also found several activation and exhaustion markers were expressed at higher frequencies in non-hospitalized convalescent samples.

Looking at these markers over time, it was apparent that immune dysregulation in the non-hospitalized individuals did not quickly resolve. Furthermore, the dysregulation of T cell activation and exhaustion markers in the non-hospitalized cohort was more pronounced in the elderly. "To our knowledge," the researchers reported, "this is the first description of sustained immune dysregulation due to COVID-19 in a large group of non-hospitalized convalescent patients."

For details of the comprehensive look at immune cells subsets during and after COVID-19 infection in hospitalized and non-hospitalized people, see the study, which includes an in-depth characterization of the activation and exhaustion phenotype of CD4+ T cells, CD8+ T cells and B cells.

The B and T cells from both patient cohorts had phenotypes consistent with activation and cellular exhaustion throughout the first two months of infection. And in the non-hospitalized individuals, the activation markers and cellular exhaustion increased over time. "These findings," Mudd and Remy said in their commentary, "illustrate the persistent nature of the adaptive immune system changes that have been noted in COVID-19 and suggest longer-term effects that may shape the maintenance of immunity to SARS-CoV-2."

A question now being explored, the UAB researchers say, is whether these observed immunologic changes are associated with symptoms experienced well beyond the acute infection, often described as "Long COVID."

Co-authors with Files, Erdmann and Goepfert in the Journal of Clinical Investigation report are Sushma Boppana, Mildred D. Perez, Sanghita Sarkar, Kelsey E. Lowman, Kai Qin, Sarah Sterrett, Eric Carlin, Anju Bansal, Steffanie Sabbaj, Olaf Kutsch and James Kobie, Division of Infectious Diseases, UAB Department of Medicine; and Dustin M. Long, Department of Biostatistics, UAB School of Public Health.

Credit: 
University of Alabama at Birmingham

Polysaccharides from red algae affect mice immune systems, say FEFU scientists

image: FEFU Center for Genomic and Regenerative Medicine

Image: 
FEFU press office

Carrageenans, biologically active polysaccharides isolated from red algae and widely used in the food industry as stabilizers, thickeners, or jelly agents have an express effect on the immune systems of mice, a study reports. The research was carried out by scientists from the School of Biomedicine of Far Eastern Federal University (FEFU), Far Eastern Branch of the Russian Academy of Sciences, and Vilnius University. A related article appears in the Journal of Biomedical Materials Research.

"The fact that carrageenan demonstrates immunosuppressive properties in a particular case does not make it generally dangerous or toxic though", says Aleksandra Kalitnik, one of the research authors, an Assistant Professor at the Department of Pharmacy and Pharmacology, FEFU School of Biomedicine.

The research reveals that carrageenans and the products of their partial degradation with low molecular weight are not pharmacologically inert. On the contrary, they are capable of suppressing the immune system. After adding carrageenans to the diet of lab mice for one week, the activity of their congenital immunity cells reduced and leukocyte count dropped.

The paper leaves many questions unanswered, but one thing is clear: although carrageenans are a permanent component of the human diet, their medical potential is extremely underestimated.

"Immunosuppressants are used to treat different disorders, such as allergies and autoimmune diseases: multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, systemic scleroderma, dermatomyositis, and others. Usually, these diseases are associated with the hyperactivation of some parts of the immune system and/or with the reduced production or functional activity of immunosuppressive cells. A misbalance between inflammation and suppression may lead to the development of an excessive immune response to a patient's own antigens. Currently, we cannot confirm carrageenans are immunosuppressants. However, we established they are able to suppress the activity of peritoneal phagocytes (abdominal immune cells) in mice. It is still unclear whether it is for good or bad. Certainly, it can be beneficial for some conditions associated with immune system hyperactivation," says Aleksandra Kalitnik.

According to the scientist, it is too soon to start thinking about the development of a carrageenan-based immunosuppressive drug. The biological properties of carrageenans require further fundamental research that might take years.

The team believes that red algae polysaccharides can react with cell receptors directly (in case of in vitro experiments) or indirectly (when taken orally). Namely, they react with the receptors of immune cells in the gastrointestinal tract that, in turn, pass the information on to the immune cells of the blood.

"We would like to find out the way carrageenans influence cell receptors and signal paths that are involved in increasing and decreasing the leukocyte level. Such a study would help us better understand the potential of carrageenans as pharmacological substances or bio-additives that could reduce immune system hyperactivation. At the current stage, we only observed the effect of immunosuppression, namely the reduction of leukocyte count and activity," added Aleksandra Kalitnik.

The study did not cover the carrageenans that are used in the food industry and consumed by people. Food carrageenans have to meet strict requirements, including the maximum allowed molecular mass and dosage. The dosages of food carrageenans are lower than those used in the experiment by several orders of magnitude. Moreover, food products do not contain pure carrageenan. It is consumed together with proteins and other substances that considerably affect its properties.

"The microbial populations of the gastrointestinal tracts of mice and men are quite different, and carrageenan might have no suppressing effect on the human immune system. To put it simply, carrageenan can become an immunosuppressor if needed and demonstrate immune-modulating properties in other cases, supporting the natural protective functions of the body. This fact is confirmed by some experimental data," concluded Aleksandra Kalitnik.

Credit: 
Far Eastern Federal University

Patient characteristics associated with telemedicine access during COVID-19 pandemic

What The Study Did: This study identified racial/ ethnic, sex, age, language, and socioeconomic differences in accessing telemedicine for primary care and specialty ambulatory care; if not addressed, these differences may compound existing inequities in care among vulnerable populations.

Authors: Srinath Adusumalli, M.D., M.Sc., of the Hospital of the University of Pennsylvania in Philadelphia, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2020.31640)

Editor's Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Credit: 
JAMA Network

Detective work in theoretical physics

image: Time axis showing the number of publications relating to dynamical density functional theory.

Image: 
M. te Vrugt et al.

Scientific articles in the field of physics are mostly very short and deal with a very restricted topic. A remarkable exception to this is an article published recently by physicists from the Universities of Münster and Düsseldorf. The article is 127 pages long, cites a total of 1075 sources and deals with a wide range of branches of physics - from biophysics to quantum mechanics.

The article is a so-called review article and was written by physicists Michael te Vrugt and Prof. Raphael Wittkowski from the Institute of Theoretical Physics and the Center for Soft Nanoscience at the University of Münster, together with Prof. Hartmut Löwen from the Institute for Theoretical Physics II at the University of Düsseldorf. The aim of such review articles is to provide an introduction to a certain subject area and to summarize and evaluate the current state of research in this area for the benefit of other researchers. "In our case we deal with a theory used in very many areas - the so-called dynamical density functional theory (DDFT)," explains last author Raphael Wittkowski. "Since we deal with all aspects of the subject, the article turned out to be very long and wide-ranging."

DDFT is a method for describing systems consisting of a large number of interacting particles such as are found in liquids, for example. Understanding these systems is important in numerous fields of research such as chemistry, solid state physics or biophysics. This in turn leads to a large variety of applications for DDFT, for example in materials science and biology. "DDFT and related methods have been developed and applied by a number of researchers in a variety of contexts," says lead author Michael te Vrugt. "We investigated which approaches there are and how they are connected - and for this purpose we needed to do a lot of work acting as historians and detectives," he adds.

The article has been published in the journal Advances in Physics, which has an impact factor of 30.91 - making it the most important journal in the field of condensed matter physics. It only publishes four to six articles per year. The first article on DDFT, written by Robert Evans, was also published in Advances in Physics, in 1979. "This makes it especially gratifying that our review has also been published in this journal," says secondary author Hartmut Löwen. "It deals with all the important theoretical aspects and fields of application of DDFT and will probably become a standard work in our field of research."

Credit: 
University of Münster

An explanation for the lack of blood oxygenation detected in many COVID-19 patients

One of the physiopathological characteristics of COVID-19 that has most baffled the scientific and medical community is what is known as "silent hypoxemia" or "happy hypoxia". Patients suffering this phenomenon, the causes of which are still unknown, have severe pneumonia with markedly decreased arterial blood oxygen levels (known as hypoxemia). However, they do not report dyspnea (subjective feeling of shortness of breath) or increased breathing rates, which are usually characteristic symptoms of people with hypoxemia from pneumonia or any other cause.

Patients with "silent hypoxemia" often suffer a sudden imbalance, reaching a critical state that can be fatal. Normally, individuals (healthy or sick) with hypoxemia report a feeling of shortness of breath and a higher breathing rate, thus increasing the body's uptake of oxygen. This reflex mechanism depends on the carotid bodies. These small organs, located on either side of the neck next to the carotid artery, detect the drop in blood oxygen and send signals to the brain to stimulate the respiratory centre.

A group of researchers from the Seville Institute of Biomedicine - IBiS/University Hospitals Virgen del Rocío y Macarena/CSIC/University of Seville, led by Dr. Javier Villadiego, Dr. Juan José Toledo-Aral and Dr. José López-Barneo, specialists in the physiopathological study of the carotid body, have suggested in the journal Function, that "silent hypoxemia" in COVID-19 cases could be caused by this organ being infected by the coronavirus (SARS-CoV-2).

This hypothesis, which has attracted the interest of the scientific community for its novelty and possible therapeutic significance, comes from experiments that have revealed a high presence of the enzyme ECA2, the protein the coronavirus uses to infect human cells, in the carotid body. In patients with COVID-19, the coronavirus circulates in the blood. Therefore, researchers suggest that infection of the human carotid body by SARS-CoV-2 in the early stages of the disease could alter its ability to detect blood oxygen levels, resulting in an inability to "notice" the drop in oxygen in the arteries. If this hypothesis, which is currently being tested in new experimental models, is confirmed, this would justify the use of activators of the carotid body independent of the oxygen sensing mechanism as respiratory stimulants in patients with COVID-19.

Credit: 
University of Seville

In plants, channels set the rhythm

image: Plants are endowed with mechanosensitive channels such as MSL that transduce mechanical oscillations into electrical signals. In static condition, the cell membrane of the model plant Arabidopsis thaliana is hardly solicited, and the MSL10 'switch' shows little activity (left-hand side). When the membrane is subjected to an oscillatory pressure mimicking the effect of the wind, the switch becomes more active (oscillation, right-hand side). This is shown schematically on the diagram in the bottom right of the figure.

Image: 
Jean-Marie Frachisse and Daniel Tran, Institut de Biologie Integrative de la Cellule (CNRS/Université Paris-Saclay).

Although plants are anchored to the ground, they spend most of their lifetime swinging in the wind. Like animals, plants have 'molecular switches' on the surface of their cells that transduce a mechanical signal into an electrical one in milliseconds. In animals, sound vibrations activate 'molecular switches' located in the ear. Scientists from the CNRS, INRAE, Ecole Polytechnique, Université Paris-Saclay and Université Clermont-Auvergne (1) have found that in plants, rapid oscillations of stems and leaves due to wind may activate these 'switches' very effectively. They could allow plants to 'listen' to the wind. This is a key advantage in preparing them for storms, by modulating their growth. This work was published in PNAS on December 28, 2020.

Credit: 
CNRS

Sugars influence cell-to-surface adhesion

image: Flagella-mediated adhesion and gliding by Chlamydomonas reinhardtii (green alga) on a solid surface (top). Using TIRF microscopy, these dynamics can be visualized and analysed (bottom).

Image: 
Lara Hoepfner

How can cells adhere to surfaces and move on them? This is a question which was investigated by an international team of researchers headed by Prof. Michael Hippler from the University of Münster and Prof. Kaiyao Huang from the Institute of Hydrobiology (Chinese Academy of Sciences, Wuhan, China). The researchers used the green alga Chlamydomonas reinhardtii as their model organism. They manipulated the alga by altering the sugar modifications in proteins on the cell surface. As a result, they were able to alter the cellular surface adhesion, also known as adhesion force. The results have now been published in the open access scientific journal eLife.

Background and methodology

In order to move, the green alga has two thread-like flagella on its cell surface. The alga actually uses these flagella for swimming, but it can also use them to adhere to surfaces and glide along them. The researchers now wanted to find out how movement and adhesion on the part of the alga can be manipulated. "We discovered that proteins on cell surfaces that are involved in this process are modified by certain sugars. If these sugar chains on the proteins are altered, this enables their properties to be altered," explains Michael Hippler from the Institute of the Biology and Biotechnology of Plants at Münster University. Experts then describe such proteins as being N-glycosylated - a modification in which carbohydrates are docked onto amino groups. Alterations to these sugar modifications by genetically manipulating the algae showed that the adhesion force of the algae and, as a result, any adhesion to surfaces were reduced. At the same time, there was no change in the cells gliding on the surface. The much-reduced force with which the mutants adhere to surfaces is therefore still sufficient, under laboratory conditions, to enable gliding to take place.

In order to study these processes, the researchers first used so-called insertional mutagenesis and the CRISPR/Cas9 method to deactivate genes which encode enzymes relevant to the N-glycosylation process. "The next step was to analyse the sugar modifications of these genetically altered algae strains using mass spectrometry methods," says Michael Hippler, explaining the team's approach. In order to visualise the cell-gliding, the researchers used a special method of optical microscopy - total internal reflection fluorescence microscopy (TIRF). This method is frequently used to carry out examinations of structures which are located very close to a surface. For this purpose, a fluorescent protein was expressed in the flagella of the algae in order to make the flagella and the cell-gliding visible.

In order to measure how much force was used in adhering the individual cells to the surface, atomic force microscopy was used and micropipette adhesion measurements were undertaken in collaboration with groups at the University of Liverpool (UK) and the Max Planck Institute of Dynamics and Self-Organization in Göttingen. "This enabled us to verify that adhesion forces in the nanometre range are reduced by altering the protein sugar modifications," adds Kaiyao Huang.

The two flagella on the green alga resemble for example not only the flagella of sperm but also other movable flagella. These are usually called 'cilia' and are also found in the human body - for example in the respiratory tracts. "If we transfer our findings to human cells, sugar-modified proteins could be used to change the interaction of sperm or cilia with all sorts of surfaces," say Kaiyao Huang and Michael Hippler.

Credit: 
University of Münster